ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment

“ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)

02 Jul 2020: ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, and its clinical trial partners, will be presenting over 20 abstracts during next week at the 23rd International AIDS Conference (AIDS 2020: Virtual), being held 6-10 July.

Because of the COVID-19 pandemic, the conference will, for the first time, be completely virtual.

Highlights from ViiV Healthcare and study partners at AIDS 2020 will include the final efficacy analysis from the global HIV Prevention Treatment Network (HPTN ) 083 study evaluating investigational long-acting cabotegravir for HIV prevention; 48-week data from CUSTOMIZE, an implementation research study on how to implement, if approved, a new, once-monthly injectable HIV treatment in US healthcare practices; and results from the Positive Perspectives Wave 2 study, providing extensive insights from more than 2,300 people living with HIV (PLHIV) in 25 countries.

ViiV Healthcare’s commitment towards ending paediatric AIDS by 2025 will be showcased with a media panel to introduce the new Positive Action Breakthrough grants alongside our global partners selected to receive ViiV Healthcare funding, and a satellite symposium on delivering an Integrated Approach for Adolescent Mothers and their Children. 

Kimberly Smith, Head of Research & Development, ViiV Healthcare, said: “The data we’re presenting at AIDS 2020 show the continued depth and focus of ViiV Healthcare’s patient-centred approach to innovation and the strength of our commitment to the community. 

We’ll be sharing the significant advances we’ve made not just for the treatment of HIV, but for prevention as well, in some of the populations most disproportionately impacted by HIV.

We’ll also share the in-depth insights gained from more than 2,300 people living with HIV that will help address their treatment needs and challenges.”

Key abstracts to be presented by ViiV Healthcare and study partners at AIDS 2020

Final efficacy analysis from the global HPTN 083 study evaluating cabotegravir for HIV prevention: The HPTN 083 study, with approximately 4,600 participants across 40 sites in North and South America, Asia and Africa, is one of the first-ever clinical trials to directly compare two active HIV prevention agents.

In a planned interim review, the independent Data and Safety Monitoring Board recommended the blinded, randomised portion of the study be stopped early and results released.

Detailed final efficacy results from this interim review will be presented at AIDS 2020.

Related News: U.S FDA issues complete response letter to ViiV Healthcare for the use of investigational cabotegravir and rilpivirine long-acting regimen for the treatment of HIV

ViiV HIV prevention trial stopped early on the efficacy

48-week findings from the implementation research study, CUSTOMIZE (Cabotegravir plus Rilpivirine in the US To Optimize and Measure Implementation and Experience): Data to be presented at AIDS 2020 will outline the quantitative findings from ViiV Healthcare’s implementation research study, CUSTOMIZE.

ViiV Healthcare worked with 24 healthcare providers and clinic administrators from eight sites to identify and evaluate approaches to implementing the investigational once-monthly, long-acting, investigational regimen of cabotegravir and rilpivirine for the treatment of HIV, into clinical practice.

Long-acting treatments have the potential to change HIV management by replacing daily pills with long-acting dosing regimens, and results from the CUSTOMIZE trial will help to find solutions to real-world challenges in implementing such treatments.

Global Positive Perspectives Wave 2 study results: ViiV Healthcare will showcase results from the second wave of Positive Perspectives research at AIDS 2020.

The study captured insights from more than 2,300 people living with HIV from 25 countries and the results highlight the importance of a holistic approach involving people living with HIV in open dialogue and joint decision-making with their healthcare providers.

The external Positive Perspectives advisory committee also developed a manifesto, in partnership with ViiV Healthcare, containing specific recommendations for policymakers to include quality of life in assessments and encourage open and active dialogue, which will be outlined at the conference.

Advancing HIV treatment and care in paediatrics: Leading the way with the delivery of innovative science-led, access-driven solutions to ensure children living with HIV are not left behind, ViiV Healthcare has made a commitment towards ending paediatric AIDS by 2025.

Among the events at AIDS 2020, ViiV Healthcare will host two sessions focusing on paediatric treatment and care:

• Paediatric Media Panel (3 July 2020, 13:30-14:30 BST): Hosted ahead of the AIDS 2020 Conference, this session will be open to registered journalists only and will introduce ViiV Healthcare’s new Positive Action Breakthrough grant supporting the work of the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children’s Fund, Aidsfonds and Paediatric AIDS Treatment for Africa, which will focus on seven priority countries.
  
  The session will also touch on the upcoming Positive Action Momentum grants for teenage mothers, which will support progress towards prevention and ultimately elimination of mother to child transmission of HIV; and showcase ViiV Healthcare’s leading role in accelerating development and access to age-appropriate formulations of the latest medicines.
  
• Delivering an Integrated Approach for Adolescent Mothers and their Children (8 July 2020, 07:00-08:00 BST): ViiV Healthcare Positive Action, together with the Coalition for Children Affected by AIDS (the Coalition), will be co-hosting a satellite symposium on HIV-affected adolescent mothers and their children at AIDS 2020.
  
  The satellite will enable the President’s Emergency Plan for AIDS Relief and the Global Fund to reflect together upon a draft advocacy agenda for HIV-affected adolescent mothers and their children, developed by 43 experts at a learning session the Coalition co-hosted with the World Health Organisation in December 2019.”
  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-on-long-acting-regimens-for-hiv-prevention-and-treatment-at-aids-2020-virtual/